Kornimate/medical-research-clean huggingface dataset:
do vacutainers with animal characters reduce fear and anxiety?

Conditions: Procedural Pain; Acute Pain; Fear; Anxiety

Summary: the study was designed as a randomized controlled experimental research with the purpose of determining the effect of distraction by using vacutainers of three different animal characters.

in the literature, it is stated that nurses should use pharmacological and non-pharmacological methods in pain and anxiety management in painful procedures. evidence-based studies are needed to show the effectiveness of non-pharmacological methods in reducing pain during invasive procedures and to investigate the effects of easy-to-apply methods on pain. in light of this information, this study aimed to compare the effects of vacutainers of three different animal characters on fear, anxiety, and pain in children during bloodletting. the study is a prospective, randomized and controlled trial.children aged 4 to 7 years who required blood draw were divided into three groups; two groups: experimental and control groups. animal characters (butterfly, peacock and rabbit) chosen by children in the experimental group was attached to the vacutainer, and then their blood was drawn. the data were obtained by face-to-face interviews with the child, parent and observer before and after the procedure. children's pain and fear/anxiety levels were evaluated using the children's fear scale and thewong-baker faces pain scale, respectively. the study population consisted of children aged 4 to 7 years who presented to the children's blood draw room of the hospital. sample of the study consisted of a total of 1800 children who met the sample selection criteria and were selected via randomization method. data were collected using the interview and observation form, children's fear scale, and wong-baker faces pain rating scale.

Eligibility criteria:
inclusion criteria: * the child was selected by simple randomization. * the child was between 4-7 years old. * the child and parent were informed and their written consent was obtained prior to the procedure. * the bloodletting procedure was performed by the same nurse. * the child was given standard information before the bloodletting procedure. * the needle used for the bloodletting procedure was of the same thickness. * the child could evaluate the pain and fear scales. exclusion criteria: * the child was excluded from the study if they had the following criteria; * the child had infection, skin integrity disturbance, and rash in the area where the procedure would be performed. * the child had nerve damage in the previously treated area. * the child's health status was critical and unstable. * the child had developmental retardation that prevents them from responding to pain and fear scales. * the child had taken any analgesic in the last 6 hours before the bloodletting procedure. * the child did not want to participate. * the child did not meet the selection criteria for the experimental and control groups.

Keywords: bloodletting animal vacutainer procedural pain fear distraction
physical literacy and rehabilitation

Conditions: Chronic Conditions, Multiple; Aging; Mobility Limitation

Summary: with the aging population, the prevalence of chronic conditions continues to rise, affecting 1/3 of canadians. the promotion of physical literacy, defined as "the motivation, confidence, physical competence and knowledge, to take responsibility for engagement in physical activity for life", has emerged as a promising strategy to increase movement for children. however, little is known about how physical literacy can impact aging adults. a working definition of physical literacy for adults focusing on mobility, function and self-monitoring provides opportunity to guide public health programs in addressing the rehabilitation needs of persons living with multiple chronic conditions.

the objectives of this three stage mixed methods study is to: 1. develop a new physical literacy framework, with the help of health professionals and end-users that promotes optimal physical functioning for adults. 2. develop a population-based health intervention using rehabilitation strategies that are delivered virtually to increase physical literacy for adults. the first 2 qualitative studies will be used to inform the third quantitative intervention. first, an on-line consensus approach with physiotherapy leaders, rehabilitation researchers and public health experts will be used to identify a new physical literacy framework as it relates to adults. second, virtual semi-structured interviews with working adults who are living with 2 or more chronic conditions will determine how aging adults frame physical literacy in their life, specifically with the management of chronic conditions. lastly, working adults with 2 or more chronic conditions will participate in a 5-week physical literacy program. multifaceted knowledge translation strategies including; "walk and talk" with a neighbour or friend, podcasts and on-line mobility challenges will be utilized. it is anticipated the intervention will improve important physical literacy outcomes such as; physical competence, function, mobility, motivation, awareness, and self-efficacy.

Eligibility criteria:
inclusion criteria: * subjects will be screened by the primary researcher for the following inclusion criteria: 1. diagnosed from a physician with 2 or more chronic conditions and have lived with the conditions for ≥1 year 2. able to speak english 3. employed full time as a teacher in the hamilton-wentworth school board, ontario between the ages of 45 and 65 years. 4. describe themselves as moderately physically active or inactive over the past 12 months exclusion criteria: * advised by physician not to participate in physical activity

Keywords: adults physical function physical literacy
evaluation of specific biomarkers in primary invasive breast cancer

Conditions: Neoplasms, Breast

Summary: this study will examine specific biomarkers in primary invasive breast cancer and explore their correlation with patient outcome following standard neoadjuvant treatment.


Eligibility criteria:
inclusion criteria: * the patient has 18 years of age or older at the time of consent. * the patient has provided pre-treatment tumor samples for wt1 expression screening and gene expression profiling in the context of the nct01220128 study. * the patient has a histologically or cytologically confirmed primary invasive breast cancer. * the patient has provided written informed consent before any new information or new material is provided to the sponsor. * the patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer. * the patient is planned to receive, is receiving or has received standard and/or investigational therapy for breast cancer. exclusion criteria: not applicable.

Keywords: tumor antigens observational breast cancer biomarkers neoadjuvant
current practice for management of pneumothorax in egypt

Conditions: Pneumothorax

Summary: there are standard well-known guidelines for pneumothorax management with minimal difference between societies and associations. we are investigating how much of these guidelines are actually being followed in different healthcare facilites in egypt. this is a questionnaire that will be sent to all healthcare givers in egypt acorss different cities and facilities with multiple choice questions presenting different case scenarios and the management options being given to the patient.


Eligibility criteria:
inclusion criteria: * being health care giver concerned with management of pneumothorax exclusion criteria: * being not concerned with management of pneumothorax
increasing the efficiency of depression-screening using patient-targeted feedback

Conditions: Depressive Episode; Chronic Ischaemic Heart Disease; Hypertension

Summary: out-patients with coronary heart disease or hypertension will fill out a depression screening questionnaire while waiting in a cardiac clinic. using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. this feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment. patients in the control group receive no direct screening-feedback but their cardiologist will be informed about the screening result. all patients with a positive screening-result will be contacted after one month and six months and asked for symptoms of depression, and their use of health care. the aim of this study is to evaluate the efficiency of this minimal intervention on the course of depressive symptom in patients with known coronary heart disease or hypertension.

the aim of this study is to evaluate the efficiency of a minimal intervention on the course of depressive symptoms in patients with known coronary heart disease (chd) or hypertension. by means of a depression screening and individual patient-targeted feedback the level of depression should decrease, the percentage of treated depressed patients should increase and health economic costs should be lowered. the main hypothesis is that screening plus targeted feedback results in a greater reduction of depression than screening only.

Eligibility criteria:
inclusion criteria: * gender: both, male and female * minimum age: 18 years * maximum age: no maximum age * attendance in a cardiac clinic; * clinical diagnosis of coronary heart disease or hypertension; * age ≥ 18 years; * sufficient language skills; * informed consent exclusion criteria: * life threatening health status; * severe somatic or/and psychological disorder that needs urgent treatment; * acute suicidal tendency; * severe cognitive or/and visual difficulties; * not being able to fill out questionnaires

Keywords: depressive episode chronic ischaemic heart disease hypertension
comparison of the alpha-2 agonists for prevention of intraocular pressure elevation after selective laser trabeculoplasty

Conditions: Glaucoma; Ocular Hypertension

Summary: the purpose of the study is to compare the safety and efficacy of two drops used to lower eye pressure when given prior to a glaucoma laser procedure.

this is a prospective randomized double blind trial of patients undergoing selective laser trabeculoplasty for primary open angle glaucoma and ocular hypertension. enrolled patients are randomized to receive one drop of brimonidine 0.1% in one eye and one drop of apraclonidine 0.5% in the fellow eye. the trabecular meshwork in both eyes of each enrolled patient is treated 360 degrees at the same sitting. intraocular pressure is measured in each eye one hour before applying the study medications and at one hour and one week after laser surgery.

Eligibility criteria:
inclusion criteria: * male or female, at least 18 years of age * open angle glaucoma with inadequate intraocular pressure (iop) control or evidence of progression (based on optic nerve head appearance and/or visual field changes) despite current medical therapy * ocular hypertension requiring lowering of iop * ability to understand and provide informed consent to participate in this study and willingness to follow study instructions and likely to complete all required visits exclusion criteria: * inability to understand and provide informed consent to participate in this study * inability/unwillingness to follow study instructions and complete all required visits * documented allergy to either brimonidine or iopidine * angle closure glaucoma * congenital/juvenile glaucoma * neovascular glaucoma * active uveitis

Keywords: glaucoma laser laser trabeculoplasty selective laser trabeculoplasty intraocular pressure
health-related quality of life in patients on anticoagulants

Conditions: Atrial Fibrillation

Summary: the present study has been designed to describe the health-related quality of life in patients with non valvular atrial fibrillation who have been prescribed a specific anticoagulant treatment for their non valvular atrial fibrilation at least 6 months prior to study initiation. it will be conducted in departments of internal medicine from approximately 50 centers in spain. it consists of an only visit that will coincide with one of those performed by the patients as part of routine follow-up of their disease. 500 patients seen in internal medicine are planned to be included in the study


Eligibility criteria:
inclusion criteria: * the patient is willing and provides written informed consent to participate in this study. * the patient is at least 18 years of age * the patient has a diagnosis of non-valvular atrial fibrillation * the patient is on the same anticoagulant therapy (vka or doac) during at least 6 months and maximum 2 years. * if treated with vka, availability of % time in therapeutic range (ttr) in past analytical records or enough amount of international normalized ratio (inr) measures to calculate it. exclusion criteria: * current participation in any clinical trial of a drug or device * contraindication to the use of doac or vka as described in the summary of product characteristics (smpc).
clinical trials for the prevention of gallstone formation after gastrectomy in patient with gastric cancer

Conditions: Gastric Cancer

Summary: this study evaluates the efficacy and safety of dwj1319 in the prevention of gallstone formation after gastrectomy in patient with gastric cancer. two-thirds of the participants will receive dwj1319, while the other will receive a placebo.


Eligibility criteria:
inclusion criteria: * male or female at least 19 years of age * patient who undergoes gastrectomy (total, distal or proximal gastrectomy) * d1+ or d2 lymph node dissection * performance status of 0 or 1 on ecog (eastern cooperative oncology group) scale * written informed consent exclusion criteria: * patients with cholangitis, cholecystitis, non-functional gall bladder, or biliary obstruction * presence of gallstones on ultrasonography and/or ct * history of previous cholecystectomy * patients undergoing pylorus-preserving gastrectomy * pregnant or lactating women and fertile women who is not using proper contraceptive method * patients with history of drug or alcohol abuse within 5 years ago
weekly docetaxel plus cisplatin as the first-line therapy for nasopharyngeal cancer

Conditions: Nasopharyngeal Cancer

Summary: the investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer


Eligibility criteria:
inclusion criteria: * histologically confirmed nasopharyngeal cancer * chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment) * ecog 0-1 * at least one measurable lesion exclusion criteria: * other cancer * pregnat * docetaxel hypersentitivity history * severe heart or pulmonary disease

Keywords: nasopharyngeal cancer weekly docetaxel cisplatin
perioperative outcome of congenital heart disease surgery in childhood

Conditions: Congenital Heart Disease

Summary: congenital heart disease is the most common congenital malformation in the world with high morbidity and mortality. however, there is no data to assess the perioperative outcome of congenital heart disease surgery among chinese cross-regional population. this study aims to investigate the perioperative outcome of congenital heart disease surgery in childhood from a chinese cross-regional cohort.


Eligibility criteria:
inclusion criteria: * subject was aged 1 week-18 years * subjects underwent congenital heart disease surgery; * available data to investigate perioperative outcome. exclusion criteria: * cardiac reoperation; * emergency surgery; * interventional procedure within prior 30 days prior to surgery; * missing outcome data.
extension of alt-801 in diabetic and non-diabetic overweight and obese subjects with (nafld)

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: this extension study will assess the safety and effects of 24 weeks of treatment with alt-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (nafld).

this extension study will enroll subjects who have completed 12 weeks of treatment in study alt-801-105. it is designed to allow for an additional 12 weeks of treatment in order to assess the safety and effects of 24 weeks of treatment with alt-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (nafld).

Eligibility criteria:
inclusion criteria: * written informed consent to participate in this extension study, signed prior to the performance of any study procedures * receipt of 12 weeks of investigational product with completion of the procedures in study alt-801-105 * women who are not pregnant or breastfeeding exclusion criteria: * meets any of the exclusion criteria in study alt-801-105 at the time of study entry * development of any of the following conditions at any time during study alt-801-105: 1. type 1 dm and/or insulin-dependent type 2 diabetes mellitus (t2dm), or uncontrolled t2dm requiring rescue therapy in study alt-801-105 2. history of pancreatitis or hypersensitivity reaction to glp-1 analogues

Keywords: obese overweight
study of hd mesh ablation system for treatment of paroxysmal atrial fibrillation

Conditions: Paroxysmal Atrial Fibrillation

Summary: this is a randomized controlled study of the bard high density mesh ablation system for treatment of paroxysmal atrial fibrillation. this study will determine if the hd mesh ablation system is as safe as and more effective than anti-arrhythmic drugs.


Eligibility criteria:
inclusion criteria: * patients with symptomatic paroxysmal atrial fibrillation who have failed at least one class i or iii anti-arrhythmic drug * other inclusion criteria exclusion criteria: * previous surgical or catheter ablation to treat af * permanent af * uncontrolled or unstable medical conditions * other exclusion criteria
cohort of ipf patients experiencing an exacerbation

Conditions: Idiopathic Pulmonary Fibrosis

Summary: extension of the pfbio cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (ipf) for longitudinal follow-up for up to 5 years. in the pfbio-exa extension, patients are included if they experience an exacerbation, or other increase in respiratory symptoms requiring hospital admission, for further collection of clinical and biological data.

the aim of this study is to investigate the diagnostic and prognostic value of clinical and blood biomarkers during exacerbations, or other increase in respiratory symptoms requiring hospital admission in patients with ipf. patients that are already included in the pfbio-cohort (nct02755441) and who are admitted to hospital with an increase in respiratory symptoms, are also included in pfbio-exa. patients are recruited within 24 hrs. from hospital admission with respiratory worsening, where clinical data, and blood samples are collected. the blood samples are investigated for the same blood biomarkers as pfbio. patient related outcomes are also collected, including quality-of-life questionnaires and outcomes of the exacerbations.

Eligibility criteria:
inclusion criteria: * admitted with an increase in respiratory symptoms * already included in pfbio or included simultaneously in pfbio and pfbio-exa * age at least 18 years exclusion criteria: * unable to provide informed consent

Keywords: exacerbation hospitalization biomarkers outcome prognosis diagnosis
a study to assess efficacy and safety of the ketoprofen vs diclofenac

Conditions: Osteoarthritis

Summary: primary objective: • to assess therapeutic efficacy of the ketoprofen compared with diclofenac based on the assessment of primary endpoint : mean change in walking arthritis pain intensity score secondary objectives: * to assess therapeutic efficacy of the ketoprofen compared with diclofenac based on the assessment of secondary endpoints. * to assess safety and tolerability of the ketoprofen compared with diclofenac based on the nature and frequency of adverse events in treatment groups

this trial is designed as an open-label, multicenter, randomized, clinical study for assessment of efficacy and safety of ketoprofen plaster and diclofenac plaster in patients with osteoarthritis

Eligibility criteria:
inclusion criteria: * patients aged 40-75 years * compliance to acr diagnostic criteria of oa of the knee * patients with kellgren-lawrence grade 1-3 * index knee pain should be ≥40 mm on vas (100mm) scale exclusion criteria: * intolerance or allergic reactions to the study therapy * usage of nsaids within 3 days * open skin lesions or dermatological conditions at the site of plaster application * surgery or major trauma of the index knee within the previous 12 months * pregnant or breast-feeding women * alcohol addiction, drug addiction or drug abuse in the past

Keywords: ketoprofen diclofenac osteoarthritis
vitamin d levels in frail elderly patients with a hip fracture

Conditions: Hip Fracture; Vitamin D Deficiency

Summary: the purpose of this study is to assess whether all frail elderly admitted with hip fracture has a vitamin d deficiency, and if s-25(oh)d deficiency increases the risk of hip fracture in frail elderly. frail elderly are defined as being 65 years of age or older, and living in nursing homes or senior housings. the investigators' hypotheses state that: 1. frail elderly with hip fractures will have a suboptimal level of vitamin d. 2. frail elderly with hip fractures are more likely to have a suboptimal level of vitamin d than frail elderly without any hip fractures during the last ten years.

the study examined frail elderly patients, defined as 65 of age or older and living nursing homes or senior housings. cases where taken from a randomised controlled trial (nct01102010), where the included where frail elderly admitted with a hip fractures to the orthopaedic surgery ward at aarhus university hospital. controls were frail elderly, without a hip fracture in the previous ten years, admitted to the geriatric ward at aarhus university hospital. the investigators will look at all eligible patients' files and record their serum-25(oh)d levels upon admission. according to sample size calculations 92 patients are needed in the case group, and 138 patients in the control group. the inclusion period will be from the 18th of january 2010 to the 1st of october 2012 for both groups.

Eligibility criteria:
inclusion criteria, cases: * aged 65 or older * living in nursing home or senior housing * admitted with hip fracture to the orthopaedic ward, aarhus university hospital exclusion criteria, cases: * no serum-25(oh)d measurement upon admission inclusion criteria, controls: * aged 65 or older * living in nursing home or senior housing * admitted to the geriatric ward, aarhus university hospital exclusion criteria, controls: * no serum-25(oh)d measurement upon admission * hip fracture in the previous ten years

Keywords: frail elderly hip fracture vitamin d geriatrics